HBIO · Harvard Bioscience, Inc.

Harvard Bioscience's investor presentation highlights a strategic pivot to translational science tools amid regulatory shifts favoring human-relevant models like organoids. FY25 results show $87M revenue more than 1.5x enterprise value as of March 13, 2026, with strong recurring revenue at 54% and leadership in 7 of 10 product lines serving 10,000+ customers. Management provides FY26 guidance signaling modest growth and margin expansion, supported by operational efficiencies. Key actions include new executive hires like CEO John Duke and CFO Mark Frost, board expansions, and a February 2026 focus on translational products. Debt refinancing to $40M structure with BroadOak extends maturities to 2029, cuts $3M annual debt service, and adds $7.5M convertible investment, enhancing flexibility. Project Viking's phased Holliston closure by Q1 2027 relocates U.S. production to Minneapolis, yielding $3M adjusted EBITDA uplift in 2027 and $4M thereafter through efficiency gains. These moves position the company to leverage preclinical cash flows for R&D in high-growth areas like MeshMEA and SoHo, bridging in vivo and in vitro platforms in a $10B+ market.